Drug Profile
NMT cP12
Alternative Names: NMT-cP12Latest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator NeoMatrix Therapeutics
- Class Peptides; Skin disorder therapies
- Mechanism of Action Platelet-derived growth factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Burns
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for phase-I development in Burns(In volunteers) in USA (IV)
- 24 Sep 2020 Phase-I clinical trials in Burns (In volunteers) in USA (IV) prior to September 2020
- 24 Sep 2020 Pharmacodynamics data from preclinical trial in Burns released by NeoMatrix Therapeutics